ELCC Complete Coverage

Patients With EGFR-expressing NSCLC Benefit From Addition of Necitumumab

Patients With EGFR-expressing NSCLC Benefit From Addition of Necitumumab

Subgroup of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) benefitted from the addition of necitumumab to gemcitabine plus cisplatin.

Immunotherapy With Live Bacterium Plus Chemo Improves Response Rate in Pleural Mesothelioma

Immunotherapy With Live Bacterium Plus Chemo Improves Response Rate in Pleural Mesothelioma

CRS-207 plus chemotherapy demonstrated encouraging clinical activity in patients with malignant pleural mesothelioma.

Osimertinib Efficacious as First-line Treatment of EGFR-mutant NSCLC

Osimertinib Efficacious as First-line Treatment of EGFR-mutant NSCLC

Osimertinib is efficacious for the first-line treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

Study Underscores Role of Osimertinib in EGFR-TKI-pretreated NSCLC

Study Underscores Role of Osimertinib in EGFR-TKI-pretreated NSCLC

Updated data from a phase 1 cohort and a pooled analysis of 2 phase 2 trials demonstrated that osimertinib therapy resulted in a high overall response rate.

Adding Bevacizumab to Maintenance Pemetrexed Improves PFS in Advanced Nonsquamous NSCLC

Adding Bevacizumab to Maintenance Pemetrexed Improves PFS in Advanced Nonsquamous NSCLC

Maintenance therapy with bevacizumab plus pemetrexed improved progression-free survival compared with pemetrexed alone.

Baseline Serum Cytokines May Be Associated With Nivolumab OS Benefit

Baseline Serum Cytokines May Be Associated With Nivolumab OS Benefit

Select serum cytokines may be associated with survival benefit in patients with advanced refractory squamous non-small cell lung cancer (NSCLC).

Despite Encouraging Activity of Osimertinib + Durvalumab, Safety Profile Warrants Further Investigation

Despite Encouraging Activity of Osimertinib + Durvalumab, Safety Profile Warrants Further Investigation

Osimertinib in combination with durvalumab demonstrated encouraging clinical activity, but the combination was associated with high rates of toxicities.

Type of Chemo in CRT Regimen Does Not Impact Brain Metastases Development

Type of Chemo in CRT Regimen Does Not Impact Brain Metastases Development

Type of chemotherapy regimen for the treatment of patients with stage 3 non-small cell lung cancer (NSCLC) does not influence who will develop brain metastases.

Durvalumab Plus Gefitinib Active in EGFR-mutant NSCLC

Durvalumab Plus Gefitinib Active in EGFR-mutant NSCLC

Durvalumab plus demonstrated encouraging activity with favorable tolerability in non-small cell lung cancer (NSCLC).

Nab-paclitaxel Plus Carboplatin Effective in Older Patients With Squamous Cell Carcinoma

Nab-paclitaxel Plus Carboplatin Effective in Older Patients With Squamous Cell Carcinoma

Treatment with nab-paclitaxel plus carboplatin resulted in significant improvement in objective response rate and overall survival.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs